US Granted Zero-Duty Status to Indian Pharma Products
The Commerce Department exempted specific patented medicines from a 100 percent import duty.
Updated on Sept. 29, 2026 in Healthcare
Live Poll
Should the U.S. prioritize zero-duty trade agreements to lower the cost of imported prescription drugs?
The United States Commerce Department has established a zero-duty framework for specific speciality pharmaceutical products imported from India and 19 other partner jurisdictions. The exemptions target medicines for rare diseases, fertility treatments, and advanced cell and gene therapies.
Why it matters
This policy adjustment aims to encourage greater domestic manufacturing of pharmaceutical products within the United States while easing trade barriers for essential treatments. It follows a series of tariff measures initiated earlier this year to regulate the import of patented drugs and biologics.
The Nifty Pharma index reached 26,831.60 on Tuesday, reflecting market reactions to the trade news. Additionally, Mankind Pharma saw its share price rise to Rs 2,480.90, marking a 1.86 per cent increase.
The players
United States Commerce Department
This federal executive department is responsible for issuing trade regulations and publishing lists of products eligible for duty exemptions.
Donald Trump
As the current President of the United States, he signed the initial executive directive in April that established the tariff framework for pharmaceutical imports.
Mankind Pharma
This is an Indian pharmaceutical company that experienced a stock price increase following the announcement of the trade exemptions.
The details
The Commerce Department published the list of eligible countries and products in the Federal Register, formalizing the relief for advanced medical items. While patented drugs and biologics remain subject to a 100 per cent duty under the broader trade regime, generic pharmaceuticals and their constituent ingredients continue to be exempt from these Section 232 tariffs.
Timeline
April 2, 2026: President Trump signed a directive on pharmaceutical imports.
July 31, 2026: Tariffs took effect for companies in the initial annex.
September 29, 2026: The US announced zero-duty exemptions for specific pharmaceutical products.
September 29, 2026: Tariffs were extended to other listed companies.
Market Landscape
This policy adjustment signifies a shift in how the US manages pharmaceutical supply chains by balancing protectionist tariff measures with the need for specialized medical imports. The move positions India as a key partner in this adjusted trade framework while impacting the valuation of major pharmaceutical firms.
The introduction of zero-duty status for specific speciality medicines may improve access to critical rare disease and gene therapies. Patients and healthcare providers should monitor if these regulatory changes lead to lower procurement costs for these advanced treatments.
The takeaway
This policy change illustrates a nuanced approach to trade where governments protect local manufacturing while maintaining access to essential high-end medical technologies. Investors and consumers should note that while patented drug tariffs remain, strategic exemptions continue to evolve.
Further reading
For more context on international trade policies and medical supplies, visit the Healthcare section.
Live Poll
Should the U.S. prioritize zero-duty trade agreements to lower the cost of imported prescription drugs?
